Evidence map›Paper›PMID 35261758›Full record

ArticleClinical kidney journal2021

Can kidney parenchyma metabolites serve as prognostic biomarkers for long-term kidney function after nephrectomy for renal cell carcinoma? A preliminary study.

Barak Rosenzweig, Pedro Recabal, Caroline Gluck, Jonathan A Coleman, Katalin Susztak, A Ari Hakimi, Edgar A Jaimes, Robert H Weiss

Open access · goldAbstract read
In one paragraph

Article in Clinical kidney journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Barak RosenzweigDepartment of Surgery, Urology Services, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Pedro RecabalDepartment of Surgery, Urology Services, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Caroline GluckDepartment of Medicine, Renal Electrolyte and Hypertension Division, University of Pennsylvania, Philadelphia, PA, USA.
Jonathan A ColemanDepartment of Surgery, Urology Services, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Katalin SusztakDepartment of Medicine, Renal Electrolyte and Hypertension Division, University of Pennsylvania, Philadelphia, PA, USA.
A Ari HakimiDepartment of Surgery, Urology Services, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Edgar A JaimesRenal Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Robert H WeissDepartment of Internal Medicine, Division of Nephrology, University of California, Davis, CA, USA.
Memorial Sloan Kettering Cancer Center · USUniversity of Pennsylvania · USTel Aviv University · ILUniversity of California, Davis · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Chronic Kidney Disease (CKD) Biomarkers Consortium Data Coordinating CenterU01DK103225 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI SCHRAUBEN, SARAH JEANNE · 2014 to 2020
$5.5M
NCI NIH HHS P30 CA008748NIDDK NIH HHS U01 DK103225
6 · The paper itself

Abstract

Objective: Nephrectomy, the standard of care for localized renal cell carcinoma (RCC), may lead to kidney function loss. Our goal was to identify prognostic biomarkers of postoperative renal function using metabolomics. Methods: Metabolomics data from benign kidney parenchyma were collected prospectively from 138 patients with RCC who underwent nephrectomy at a single institution. The primary endpoint was the difference between the postoperative and preoperative estimated glomerular filtration (eGFR) rate divided by the elapsed time (eGFR slope). eGFR slope was calculated ∼2 Results: Data were compiled on 78 patients (median age 62.6 years, 65.4% males). The mean follow Conclusions: Nephrectomy type, gender, blood lipids and benign parenchyma metabolites at nephrectomy were associated with long-term kidney function. On further study, these metabolites may be useful as potential biomarkers and to identify novel therapeutic targets for malignancy-associated renal disease.

Indexed as

chronic kidney diseasefatty acid oxidationkidney functionmetabolomicsnephrectomyrenal cell carcinoma

Identifiers

PMID35261758
PMCPMC8894921
OpenAlexW3095313934

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.